Valeritas Holdings, Inc.
(Exact name of registrant as specified in its charter)
________________________
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
001-38038
|
46-5648907
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
750 Route 202, Suite 600
Bridgewater, NJ
(Address of principal executive offices)
|
08807
(Zip Code)
|
|
|
|
Registrant's telephone number, including area code
(908) 927-9920
(Former name or former address, if changed since last report)
________________________
|
Check the appropriate box below if the Form 8‑K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
☐
|
Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12).
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b)).
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
|
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common stock, par value $0.001 per value
|
VLRX
|
The Nasdaq Capital Market
|
Item 8.01. Other Events.
On July 9, 2019, Valeritas Holdings, Inc. announced that its V-Go® Wearable Insulin Delivery device has been recently adopted on the following managed care formularies: (i) Cigna Commercial as Preferred; (ii) Humana Commercial as Preferred; and (iii) CVS Preferred Drug List. Adoption on managed care formularies with preferred formulary status will allow patients easier access to V-Go and at a lower out of pocket cost than a non-preferred or non-formulary status.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Valeritas Holdings, Inc.
Dated: July 9, 2019 By:
s/ John E. Timberlake
Name: John E. Timberlake
Title: Chief Executive Officer